EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Cabozantinib Monotherapy for Metastatic Renal Cell Carcinoma Involving Hemodialysis: Two Case Reports

Taketoshi Nara, Kengo Furihata, Kazuma Sato, Takuma Sato, Naoko Honma, Yohei Horikawa, Naotake Shimoda

IJU Case Reports · 2026-11 · 9 (6)

DOI: 10.1002/iju5.70291 ↗
AbstractBibliografische Angaben

Abstract

ABSTRACT Introduction Data on cabozantinib monotherapy for metastatic renal cell carcinoma in patients requiring hemodialysis are scarce. We present two cases: initiation before hemodialysis with subsequent continuation and initiation during maintenance hemodialysis. Case Presentation Case 1 was a 77‐year‐old man with lung metastasis who received cabozantinib after multiple systemic therapies. Cabozantinib was started at 20 mg/day before hemodialysis; hemodialysis began 8 months later, and treatment continued for 59 months with tolerability‐guided schedule modification. Case 2 was a 69‐year‐old man on maintenance hemodialysis who received cabozantinib 20 mg/day for lung and bone metastases. The schedule was changed to alternate‐day dosing. Partial response was achieved, but treatment was discontinued after 4 months because of worsening general condition. Conclusion Cabozantinib was administered with individualized dose adjustment and careful monitoring; further clinical and pharmacokinetic data are needed to establish optimal dosing.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →